Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsWith over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications. Highlights
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsAntibody is the most widely used reagent in scientific research, and most antibody suppliers mainly produce polyclonal antibodies. However, due to the inter-batch differences of polyclonal antibodies, researchers have been perplexed by the "repeatability problems" brought about by polyclonal antibodies, which greatly hinders research progress. Therefore, although polyclonal antibodies are widely used in life science research, their challenges and shortcomings need to be paid attention to.
At present, the standard method of polyclonal antibody production is to mix the antibodies isolated from several experimental animals (usually 2–20 animals) to improve the reliability. However, this method usually provides only a "general level" of antibodies, and the specificity and sensitivity are often not satisfactory. A new solution is put forward from the point of view of antibody sequencing: the antibody produced by each animal can be screened and identified by immunoprecipitation, Western Blot, ELISA, and other experiments, and then the polyclonal antibody is sequenced, and then the antibody is produced by recombinant protein expression, which not only reduces the difference between batches, but also produces a better antibody product than the "general level". Polyclonal antibody sequencing is based on mass spectrometry de novo sequencing that can sequence antibody proteins directly from blood or polyclonal antibody (pAb) to obtain monoclonal antibody (mAb) amino acid sequence.
Fig. 1 Antibody Production
Therefore, polyclonal antibody sequencing can directly and efficiently find natural antibodies that play a role in the immune system and have high affinity, which is convenient for the production of recombinant antibodies with stronger specificity and higher sensitivity than natural antibodies.
Our optional protein sequencing services:
At present, scientists mainly rely on gene sequencing to find and identify antibodies from the blood, and the most commonly used is to sequence the mRNA of peripheral blood B cell receptor (BCR) by next generation sequencing (NGS). This BCR sequencing technique can comprehensively and rapidly detect the targeted amplified BCR and obtain large-scale sequence information for B cell receptors. This information can indirectly indicate the composition of antibodies in the immune response. Usually, in order to further screen useful sequence information, flow cytometry or immunoprecipitation targeting specific antigens is used to enrich and characterize B cell subsets before sequencing. However, relying solely on B cell receptor sequencing to identify antibodies in the blood will bring some limitations and deficiencies.
First of all, B cells are generated in the bone marrow, and when they mature, they migrate out of the peripheral blood and enter the spleen and lymph nodes. However, at present, the B cells sequenced by BCR only come from circulating peripheral blood, so they only represent a small part of the total B cell population, while the B cells stimulated by antigen are more distributed in the spleen and lymph nodes, which forms a blind area for detection. Second, without effective enrichment, most of the B cells in peripheral blood are only natural B cells and are not directly related to the immune response. This will interfere with the accuracy of data analysis and results. Finally, only a small portion of the receptors on the surface of B cells will eventually be secreted into the serum to form soluble functional antibodies.
Although the genomic information of B-cell receptors is very important when antibodies are found in the blood, it alone cannot accurately evaluate serum antibodies. However, the antibodies analyzed by proteomics are functional antibodies, so accurate and complete antibody information can be captured.
The most important reason why protein sequencing is more advantageous can be summed up in one sentence: cells are harder to obtain than proteins. For example, if the cell line is lost due to sudden or accidental reasons, but there is still a very small amount of antibody proteins, we can sequence these proteins to "regenerate" the lost antibodies. For example, in immunized animals, antigen-specific antibodies are abundant in the blood, and the cells that produce these antibodies are mainly found in tissues such as the spleen, and it is obviously much easier to obtain blood than cells. This is especially true when sampling the human body.
Fig. 2 Schematic of single B cell capture, library construction, and sequencing. (Leonard D. Goldstein, 2019)
Our BCR repertoire analysis services:
Development of biomarkers for the diagnosis of disease: In cancer, vaccines, and autoimmune diseases, our immune system produces antibodies against specific antigens. By sequencing the antibodies in the circulating blood, we can find important information about the immune system, which can be used to diagnose diseases.
Development of antibody drugs for disease treatment: Polyclonal antibody sequencing helps researchers find new antibody drugs directly from the blood of immunized animals or human patients. The characteristic of finding antibodies in human blood will have a wide application prospect because the immunogenicity of human antibodies in clinical use is greatly reduced, which increases the safety and success rate of antibody drug research and development.
Conversion of polyclonal antibodies to monoclonal antibodies to achieve large-scale production: Polyclonal antibody sequencing can eliminate the "repeatability problem" faced by traditional antibody production techniques. It is helpful to expand the scale of antibody production and development by transforming the complex multi-antibody mixture into the form of monoclonal antibodies and then carrying out high-unity recombinant expression.
On the basis of bioinformatics algorithms and mass spectrometry-based proteomics, combined with the latest research progress in protein sequencing and protein chemistry, the Creative Biolabs sequencing process starts with antibody protein samples or post-immunized blood samples. Firstly, we purified the samples by affinity purification and enzyme digestion, and determined them by liquid chromatography tandem mass spectrometry (LC-MS/MS). Then we used the unique bioinformatics software to analyze and process the MS data, which was finally evaluated by proteomics experts, and obtained the full-length antibody sequence paired with heavy and light chains, which can be used for subsequent recombinant expression and testing.
Our de novo antibody sequencing services:
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
